Chiesi announced it has secured from UCB rights to zampilimab, a monoclonal antibody being investigated to treat idiopathic…
Articles by Marisa Wexler, MS
LYT-100 (deupirfenidone), an experimental oral therapy containing a similar active ingredient to Esbriet, was well-tolerated at all tested…
The American Thoracic Society (ATS) has premiered a docuseries called “Helping the World to Breathe,” showcasing the society’s commitment…
The National Institutes of Health (NIH) has awarded a grant to support research into immune mechanisms that could allow for…
Reviva Pharmaceuticals is planning to seek the U.S. Food and Drug Administration’s (FDA) permission to begin Phase 2 clinical…
Agomab Therapeutics and Origo Biopharma are joining forces to develop new therapies for pulmonary fibrosis (PF) and…
Healthcare providers should broach the topic of palliative care — specialized care that may or may not include hospice —…
Smoking cigarettes substantially increases the risk of developing idiopathic pulmonary fibrosis (IPF), according to a population-based study conducted in…
A new diagnostic tool, the Envisia Genomic Classifier, can help make doctors more confident and accurate in diagnosing…
RXC007, an investigational oral therapy for idiopathic pulmonary fibrosis (IPF), is showing favorable safety and pharmacological properties in an ongoing…